Abstract
Urothelial carcinoma accounts for more than 90% of bladder tumors. In locally advanced and metastatic tumors, chemotherapy has been the only option for systemic treatment for a long time, with the best responses achieved with cisplatin-based regimens.
Nowadays we have the possibility to use new drugs like immunotherapy and targeted therapy. These promising drugs include the anti-PD-L1 monoclonal antibody avelumab (Bavencio(C)), which has been shown to be effective in the first-line maintenance in patients without progression after cisplatin therapy (JAVELIN study).
However, there is no payment from public health insurance for avelumab in this indication in the Czech Republic.